Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Ken-Ichiro Fukuchi has a total of 51 co-authors. Here are the top co-authors by number of shared publications:

  • Jinghong Kou

    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria, Peoria, USA

    11 shared publications
  • Robert Lalonde

    Université de Lorraine, Laboratoire Stress, Immunité, Pathogènes (UR SIMPA)

    9 shared publications
  • Jeong-Eun Lim

    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria, Peoria, USA

    8 shared publications
  • Junling Yang

    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine Peoria

    8 shared publications
  • Abhinandan Pattanayak

    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, P.O. Box 1649, Peoria, IL 61656, USA

    7 shared publications
  • Min Song

    Department of Cancer Biology and Pharmacology, University of Illinois College of Medicine at Peoria, Peoria, Illinois 61656, USA

    6 shared publications

Latest Publications

  • Open Access

    Editorial: Exploring miRNA roles in neuroinflammation and brain aging: mechanisms and therapeutic potential

    by Ken-Ichiro Fukuchi, Junling Yang, Joanna Williams

    Pathophysiology. Previous studies have indicated that the NLRP3 inflammasome drives pyroptosis and plays a significant role in promoting SCI (1,2). Alongside this, decreased levels of the anti-inflammatory and anti-apoptotic miRNA, miR-128-3p (3), have been reported in microglia in an SCI model (4). Based on these previous studies, Yang S. et al. investigated a pyroptosis signaling pathway modulated by miR-128-3p in SCI. They confirmed that SCI decreased expression levels of miR-128-3p in the spinal cord tissues in their SCI mouse model as well as in two different Gene Expression Omnibus SCI data sets that contain non-coding RNA expression profiles. They show that intrathecal injection of agomir-miR-128-3p suppresses oxidative stress, pyroptosis and inflammation and improves functional recovery in SCI mice.They confirmed TXNPI as a direct target of miR-128-3p by a luciferase reporter assay and in vivo immunohistochemistry. These observations were also confirmed in an SCI cell model (LPStreated BV2 microglial cells) by transfection of miR-128-3p mimics. By performing the series of elegant in vitro and in vivo experiments involving miR-128-3p promoter-driven luciferase activity, ChIP qRT-PCR assays, and overexpression of FOXO3 in the SCI cell model, they clearly demonstrated that FOXO3 is a transcription factor that drives expression of miR-128 in these SCI models. They have identified the FOXO3/mir-128-3p/TXNIP/NLRP3-mediated pyroptosis pathway as a potential therapeutic target for SCI.MiR-34a is also involved in inflammatory processes (5) and is overexpressed in the brains of individuals with Alzheimer's disease (AD) (6). It has been implicated in cancer, metabolic diseases, and cardiovascular diseases (7,8), all of which are associated with an altered AD risk (9)(10)(11). Additionally, miR-34a levels increase in both the blood and brain with aging (12), and it has been proposed as a promising diagnostic biomarker for AD (13). To investigate its role in AD pathophysiology, Yang J. et al. generated Tg-SwDI mice with constitutive miR-34a deficiency. Morris water maze testing showed that Tg-SwDI mice exhibited impaired learning compared with non-transgenic littermates, while miR-34a deficiency improved spatial long-term memory in both genotypes. Despite this cognitive improvement, miR-34a deficiency increased activated microglia and cortical soluble Aβ40, as well as insoluble Aβ40 and Aβ42, in Tg-SwDI mice (soluble Aβ42 was undetectable by ELISA). This apparent discrepancy was reconciled by a reduced Aβ42/Aβ40 ratio together with increased expression of the pre-and postsynaptic proteins (synaptophysin and PSD-95, respectively). These findings are consistent with previous studies showing that the Aβ42/Aβ40 ratio, rather than the absolute abundance of Aβ peptides, is a more important determinant of neurotoxic Aβ conformations (14). Bulk RNA-seq analysis of hippocampal tissue further revealed that miR-34a deficiency upregulated genes involved in type I interferon signaling, suggesting induction of interferonresponsive microglia (IRM). These findings indicate that miR-34a contributes to AD pathogenesis by modulating Aβ homeostasis and microglial activation, highlighting it as a potential therapeutic target.the earliest stages of definitive relapsing-remitting multiple sclerosis (RRMS) to identify cerebrospinal fluid (CSF) biomarkers associated with early disease pathogenesis. The study quantified cell-free CSF levels of several microRNAs previously proposed as candidate biomarkers for MS. Among these, miRNA-106a-5p was significantly upregulated in patients with RRMS compared with individuals with other neurological disorders (OND). Furthermore, CSF miRNA-106a-5p levels demonstrated a strong positive correlation with the number of oligoclonal bands (OCBs), a hallmark of intrathecal immunoglobulin synthesis and a well-established indicator of central nervous system immune activation in MS. Bioinformatic and functional analyses have implicated miRNA-106a-5p in key immune regulatory pathways, including transforming growth factor-β (TGF-β), nuclear factor kappa B (NF-κB), and phosphoinositide 3kinase/protein kinase B (PI3K-AKT) signaling. Nevertheless, the precise mechanistic contribution of miRNA-106a-5p to MS pathogenesis remains to be fully elucidated. These findings identify miRNA-106a-5p as a promising early CSF biomarker for RRMS.In Mini Review, Zabalza et al. present a concise review on recent progresses in our understanding of the roles of miRNAs in MS and provided their future perspective on miRNA therapeutics. The review begins with succinct description of miRNA biogenesis, nomenclature, biological function, and two different forms of miRNAs (cell-free and exosomal miRNAs) in body fluids. This general description of miRNAs is followed by summary of our current knowledge on MS pathophysiology, clinical classification, diagnosis and therapy. These general descriptions facilitate readers' understanding of roles of miRNAs in MS pathogenesis, biomarker, and potential therapy. For cell-free miRNAs, the review found the pathogenic roles of about a dozen miRNAs in MS and identified biomarker potentials for diagnosis, prognosis and drug response in more than a dozen miRNAs. For exosomal miRNAs, the pathogenetic roles of 4 different miRNAs and a panel of 9 miRNAs discriminating relapsing remitting MS from progressive forms of MS (15) are reviewed. Additionally, miR-367-3p-containing exosomes derived from bone marrow mesenchymal stem cells are described as a potential therapeutic agent since animal models of MS are successfully treated with the agent (16). For future directions, Zabalza et al. describe developing technical approaches, limitations, and challenges of miRNA therapeutics that aim at restoring altered expression levels of miRNAs in diseases. Such approaches are generally applicable to various diseases including...

  • Open Access

    MiR-34a deficiency enhances nucleic acid sensing and type I IFN signaling in a mouse model of Alzheimer’s disease

    by Junling Yang, George Elliot Tsourdinis, Charlotte Holas, Mark Maienschein-Cline, Robert Lalonde, Ken-Ichiro Fukuchi

    Background: A number of microRNAs are implicated in aging, cell senescence, inflammation, and neurodegenerative diseases. Particularly, miR-34a levels in the brain are increased in Alzheimer's disease (AD) but its mechanistic role in AD pathogenesis is unknown. Methods: In order to investigate the role of miR-34a in AD, we produced an AD mouse model, Tg-SwDI mice, with whole body/constitutive miR-34a knockout (KO). Their cognitive function was evaluated by Morris water maze. Immunohistochemistry and immunofluorescence were used for neuropathological evaluation. Bulk RNA-seq followed by bioinformatics was used for hippocampal transcriptomics. The effect of miR-34a knockdown on expression of interferon-stimulated genes (ISG) was determined using cultured microglial cells and quantitative PCR. Results: MiR-34a KO improved long-term memory in Tg-SwDI mice, which was associated with decreases in the ratio of insoluble Aβ42 to Aβ40 and with increases in soluble and insoluble Aβ40 in the cerebral cortex. Anti-Iba1 immunofluorescence revealed increases in activated microglia. Bulk RNA-sequencing of the hippocampus followed by a gene set enrichment analysis (Enrichr) identified “cellular response to type I interferon” and “type I interferon signaling pathway” as the most prominent gene sets in miR-34a KO Tg-SwDI mice compared to miR-34a wild-type Tg-SwDI mice. Many interferon-stimulated genes (ISGs) that characterize interferon responsive microglia (IRM) were upregulated in miR-34a KO Tg-SwDI mice. MiR-34a knockdown strongly enhanced ISGs expression in TLR7 ligand-stimulated BV2 and primary microglia. Conclusion: Our results suggest that miR-34a inhibits the transition of microglia to the IRM state that may modulate synaptic and cognitive functions in neurodegenerative diseases and aging.


  • Open Access

    MiR-34a deficiency enhances nucleic acid sensing and type I IFN signaling in a mouse model of Alzheimer’s disease

    by Junling Yang, George Elliot Tsourdinis, Charlotte Holas, Mark Maienschein-Cline, Robert Lalonde, Ken-Ichiro Fukuchi

    MiR-34a is implicated in aging, cell senescence, inflammation, and neurodegenerative diseases. In order to investigate the role of miR-34a in Alzheimer’s disease (AD), we produced an AD mouse model, Tg-SwDI mice, with whole body/constitutive miR-34a knockout (KO). MiR-34a KO improved long-term memory in Tg-SwDI mice, which was associated with decreases in the ratio of insoluble Aβ42 to Aβ40 and with increases in soluble and insoluble Aβ40 in the cerebral cortex. Anti-Iba1 immunofluorescence revealed increases in activated microglia. Bulk RNA-sequencing of the hippocampus followed by a gene set enrichment analysis (Enrichr) identified “cellular response to type I interferon” and “type I interferon signaling pathway” as the most prominent gene sets in miR-34a KO Tg-SwDI mice compared to miR-34a wild-type Tg-SwDI mice. Many interferon-stimulated genes (ISGs) that characterize interferon responsive microglia (IRM) were upregulated in miR-34a KO Tg-SwDI mice. MiR-34a knockdown strongly enhanced ISGs expression in TLR7 ligand-stimulated BV2 microglia. These results suggest that miR-34a inhibits the transition of microglia to the IRM state that may modulate synaptic and cognitive functions in neurodegenerative diseases and aging.


  • Open Access

    TIR-Domain-Containing Adaptor-Inducing Interferon-β (TRIF) Is Involved in Glucose Metabolism in Adipose Tissue through the Insulin/AKT Signaling Pathway

    by Junling Yang, Ken-Ichiro Fukuchi

    Obesity significantly increases the risk of developing type 2 diabetes mellitus and other metabolic diseases. Obesity is associated with chronic low-grade inflammation in white adipose tissues, which is thought to play an essential role in developing insulin resistance. Many lines of evidence indicate that toll-like receptors (TLRs) and their downstream signaling pathways are involved in development of chronic low-grade inflammation and insulin resistance, which are associated with obesity. Mice lacking molecules positively involved in the TLR signaling pathways are generally protected from high-fat diet-induced inflammation and insulin resistance. In this study, we have determined the effects of genetic deficiency of toll/interleukin-1 receptor-domain-containing adaptor-inducing interferon-β (TRIF) on food intake, bodyweight, glucose metabolism, adipose tissue macrophage polarization, and insulin signaling in normal chow diet-fed mice to investigate the role of the TRIF-dependent TLR signaling in adipose tissue metabolism and inflammation. TRIF deficiency (TRIF−/−) increased food intake and bodyweight. The significant increase in bodyweight in TRIF−/− mice was discernible as early as 24 weeks of age and sustained thereafter. TRIF−/− mice showed impaired glucose tolerance in glucose tolerance tests, but their insulin tolerance tests were similar to those in TRIF+/+ mice. Although no difference was found in the epididymal adipose mass between the two groups, the percentage of CD206+ M2 macrophages in epididymal adipose tissue decreased in TRIF−/− mice compared with those in TRIF+/+ mice. Furthermore, activation of epididymal adipose AKT in response to insulin stimulation was remarkably diminished in TRIF−/− mice compared with TRIF+/+ mice. Our results indicate that the TRIF-dependent TLR signaling contributes to maintaining insulin/AKT signaling and M2 macrophages in epididymal adipose tissue under a normal chow diet and provide new evidence that TLR4-targeted therapies for type 2 diabetes require caution.


  • Lipopolysaccharide-Induced Exosomal miR-146a Is Involved in Altered Expression of Alzheimer’s Risk Genes Via Suppression of TLR4 Signaling

    by Junling Yang, Fiona Malone, Michelle Go, Jinghong Kou, Jeong-Eun Lim, Robert C. Caughey, Ken-Ichiro Fukuchi

    Repeated exposure to toll-like receptor 4 (TLR4) ligands, such as lipopolysaccharide (LPS), reduces responses of monocytes/macrophages to LPS (LPS/endotoxin tolerance). Microglial exposure to Aβ deposits, a TLR4 ligand, may cause “Aβ/LPS tolerance,” leading to decreased Aβ clearance. We demonstrated that microglial activation by LPS is diminished in Aβ deposit-bearing 12-month-old model mice of Alzheimer’s disease (AD), compared with non-AD mice and Aβ deposit-free 2-month-old AD mice. Because miR-146a plays a predominant role in inducing TLR tolerance in macrophages and because miR-146a in extracellular vesicles (EVs) shed by inflammatory macrophages increases in circulation, we investigated potential roles of miR-146a and inflammatory EVs in inducing TLR tolerance in microglia and in altering expression of inflammatory AD risk genes. We found that miR-146a upregulation induces TLR tolerance and alters expression of inflammatory AD risk genes in response to LPS treatment in BV2 microglia. LPS brain injection altered expression of the AD risk genes in 12-month-old AD mice but not in non-AD littermates. EVs from inflammatory macrophages polarize BV2 microglia to M1 phenotype and induce TLR tolerance. Microglia exposed to Aβ in the brain show reduced cytokine responses to systemic inflammation due to peripheral LPS injection, indicating TLR/Aβ tolerance in microglia. Our results suggest that increased miR-146a induces microglial Aβ/LPS tolerance and that circulating EVs shed by inflammatory macrophages contribute to microglial Aβ/LPS tolerance, leading to reduced Aβ clearance. Our study also suggests that altered expression of inflammatory AD risk genes may contribute to AD development via the same molecular mechanism underlying LPS tolerance.


  • Catalytic Immunoglobulin Gene Delivery in a Mouse Model of Alzheimer’s Disease: Prophylactic and Therapeutic Applications

    by Jinghong Kou, Junling Yang, Jeong-Eun Lim, Abhinandan Pattanayak, Min Song, Stephanie Planque, Sudhir Paul, Ken-Ichiro Fukuchi

    Accumulation of amyloid beta-peptide (Aβ) in the brain is hypothesized to be a causal event leading to dementia in Alzheimer’s disease (AD). Aβ vaccination removes Aβ deposits from the brain. Aβ immunotherapy, however, may cause T cell- and/or Fc-receptor-mediated brain inflammation and relocate parenchymal Aβ deposits to blood vessels leading to cerebral hemorrhages. Because catalytic antibodies do not form stable immune complexes and Aβ fragments produced by catalytic antibodies are less likely to form aggregates, Aβ-specific catalytic antibodies may have safer therapeutic profiles than reversibly-binding anti-Aβ antibodies. Additionally, catalytic antibodies may remove Aβ more efficiently than binding antibodies because a single catalytic antibody can hydrolyze thousands of Aβ molecules. We previously isolated Aβ-specific catalytic antibody, IgVL5D3, with strong Aβ-hydrolyzing activity. Here, we evaluated the prophylactic and therapeutic efficacy of brain-targeted IgVL5D3 gene delivery via recombinant adeno-associated virus serotype 9 (rAAV9) in an AD mouse model. One single injection of rAAV9-IgVL5D3 into the right ventricle of AD model mice yielded widespread, high expression of IgVL5D3 in the unilateral hemisphere. IgVL5D3 expression was readily detectable in the contralateral hemisphere but to a much lesser extent. IgVL5D3 expression was also confirmed in the cerebrospinal fluid. Prophylactic and therapeutic injection of rAAV9-IgVL5D3 reduced Aβ load in the ipsilateral hippocampus of AD model mice. No evidence of hemorrhages, increased vascular amyloid deposits, increased proinflammatory cytokines, or infiltrating T-cells in the brains was found in the experimental animals. AAV9-mediated anti-Aβ catalytic antibody brain delivery can be prophylactic and therapeutic options for AD.


  • Muscle-Directed Anti-Aβ Single-Chain Antibody Delivery via AAV1 Reduces Cerebral Aβ Load in an Alzheimer’s Disease Mouse Model

    by Junling Yang, Abhinandan Pattanayak, Min Song, Jinghong Kou, Hiroaki Taguchi, Sudhir Paul, Selvarangan Ponnazhagan, Robert Lalonde, Ken-Ichiro Fukuchi

    We previously reported that anti-amyloid-beta (Aβ) single-chain antibody (scFv59) brain delivery via recombinant adeno-associated virus (rAAV) was effective in reducing cerebral Aβ load in an Alzheimer’s disease (AD) mouse model without inducing inflammation. Here, we investigated the prophylactic effects and mechanism of a muscle-directed gene therapy modality in an AD mouse model. We injected rAAV serotype 1 encoding scFv59 into the right thigh muscles of 3-month-old mice. Nine months later, high levels of scFv59 expression were confirmed in the thigh muscles by both immunoblotting and immunohistochemistry. As controls, model mice were similarly injected with rAAV1 encoding antihuman immunodeficiency virus Gag antibody (scFvGag). AAV1-mediated scFv59 gene delivery was effective in decreasing Aβ deposits in the brain. Compared with the scFvGag group, levels of Aβ in cerebrospinal fluid (CSF) decreased significantly while Aβ in serum tended to increase in the scFv59 group. AAV1-mediated scFv59 gene delivery may alter the equilibrium of Aβ between the blood and brain, resulting in an increased efflux of Aβ from the brain owing to antibody-mediated sequestration/clearance of peripheral Aβ. Our results suggest that muscle-directed scFv59 delivery via rAAV1 may be a prophylactic option for AD and that levels of CSF Aβ may be used to evaluate the efficacy of anti-Aβ immunotherapy.